Nordicus Partners Corporation Reports 100% Revenue Increase but Faces $2.9 Million Net Loss

Nordicus Partners Corporation reported a significant increase in revenue for the fiscal year ending March 31, 2025, generating $5,000 from consulting services, a 100% rise from $2,500 in the previous year. However, the company also faced substantial operating expenses, totaling $2.9 million, compared to $310,088 in the prior year, leading to a net loss of $2.9 million, up from a loss of $298,202 in the previous fiscal year. The increase in expenses was primarily attributed to higher officer compensation, professional fees related to acquisitions, and research and development costs associated with its newly acquired subsidiaries.

The company underwent several strategic developments during the fiscal year, including the acquisition of Orocidin A/S and Bio-Convert A/S, both preclinical-stage biotechnology firms. The acquisition of Orocidin, completed on May 13, 2024, involved the issuance of 3.8 million shares of common stock valued at $19 million. Subsequently, on November 11, 2024, Nordicus acquired Bio-Convert for 12 million shares, valued at $39 million. These acquisitions are part of Nordicus's strategy to enhance its portfolio in the life sciences sector, focusing on innovative treatments for periodontitis and oral leukoplakia.

Operationally, Nordicus has expanded its portfolio to include two biotechnology companies, Orocidin and Bio-Convert, which are developing novel treatments for significant medical conditions. Orocidin has completed a 14-day toxicology study and a Beagle Dog study, demonstrating the efficacy of its lead product, QR-01, in treating periodontitis. Bio-Convert has received positive feedback from the Danish Medicines Agency regarding its treatment for oral leukoplakia, indicating a potential pathway to human trials. The company’s total assets surged to $70.2 million as of March 31, 2025, primarily due to the acquisitions, while its liabilities increased to $10.4 million.

The company’s workforce has also seen changes, with the appointment of new directors and the resignation of others, reflecting ongoing organizational adjustments. As of March 31, 2025, Nordicus had 17.3 million shares of common stock outstanding, a significant increase from 1.1 million shares the previous year, following the stock issuances related to acquisitions. The company’s accumulated deficit reached $46.8 million, raising concerns about its ability to sustain operations without additional financing.

Looking ahead, Nordicus Partners Corporation faces challenges in achieving profitability and managing its cash flow, as indicated by its substantial net loss and accumulated deficit. The company plans to finance its operations through existing cash reserves and potential capital raises. Management remains optimistic about the future, focusing on the successful development of its portfolio companies and the potential for significant returns in the life sciences market. However, the ability to continue as a going concern remains uncertain, contingent on the successful execution of its strategic initiatives and the generation of profitable operations.